Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Daily News

FDA Issues Early Alert About Risks of Peripheral Atherectomy Device

L.A. McKeown

February 07, 2025

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Daily News

Routine IVUS in Peripheral Interventions Supported by Small RCT

L.A. McKeown

March 09, 2022

News Opinion CV Team Dispatch

June 2021 News Roundup

L.A. McKeown

June 01, 2021

News Conference News VIVA 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

L.A. McKeown

November 09, 2020

News Conference News LINC 2020

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

L.A. McKeown

February 06, 2020

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

L.A. McKeown

August 03, 2017

News Daily News

Drug-Coated Balloon Gets Expanded Indication for In-Stent Restenosis in PAD

Todd Neale

September 13, 2016

News Conference News VEITH 2015

DCBs for Femoropoliteal Disease: What’s Now and What’s Next?

Yael L. Maxwell

November 19, 2015

News Daily News

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

Yael L. Maxwell

June 26, 2015

News Daily News

ISET Abstracts Shed Light on Novel Therapies for PAD

Caitlin E. Cox

February 04, 2015

News Daily News

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Salynn Boyles

December 15, 2014

News Daily News

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

Caitlin E. Cox

October 24, 2014

News Daily News

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Caitlin E. Cox

October 24, 2014

Presentation TCT 2014

EXCITE ISR: A Prospective, Randomized Trial of Excimer Laser Atherectomy Versus Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis

Presenter: Ajay J. Kirtane, Deepak L. Bhatt, Eric J. Dippel

September 16, 2014

Presentation TCT 2014

DCB Use in the Real World I: In-Stent Restenosis Insights From the FAIR Trial

Presenter: Kenneth Rosenfield, Thomas Zeller, Raghu Kolluri

September 15, 2014

News Daily News

Los Balones liberadores de Fármacos Reducen la Reestenosis y la RLD en Pacientes Diabéticos con ICE

Yael L. Maxwell

February 26, 2014

News Daily News

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Yael L. Maxwell

February 26, 2014

News Daily News

Zilver PTX 2-Year Results Published: Superior Safety, Efficacy vs. Angioplasty Sustained

April 12, 2013

Advertisement

FDA Issues Early Alert About Risks of Peripheral Atherectomy Device

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

Routine IVUS in Peripheral Interventions Supported by Small RCT

June 2021 News Roundup

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

Drug-Coated Balloon Gets Expanded Indication for In-Stent Restenosis in PAD

DCBs for Femoropoliteal Disease: What’s Now and What’s Next?

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

ISET Abstracts Shed Light on Novel Therapies for PAD

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

EXCITE ISR: A Prospective, Randomized Trial of Excimer Laser Atherectomy Versus Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis

DCB Use in the Real World I: In-Stent Restenosis Insights From the FAIR Trial

Los Balones liberadores de Fármacos Reducen la Reestenosis y la RLD en Pacientes Diabéticos con ICE

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Zilver PTX 2-Year Results Published: Superior Safety, Efficacy vs. Angioplasty Sustained

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content